Articles related to PSYCHEDELICS

A single-day inhaled mebufotenin regimen produced rapid, sustained symptom reductions through day 8 in 10 patients with postpartum depression, but the uncontrolled trial provides an early clinical signal rather than comparative efficacy evidence.

The FDA granted Breakthrough Therapy designation to DT120, an oral lysergide formulation under investigation for major depressive disorder, based on phase 3 findings suggesting rapid and sustained antidepressant effects, though the treatment remains investigational and unapproved.

Prior ayahuasca experience was associated with lower self-reported depression, stress, and alcohol use among Brazilian ceremony participants, while also correlating with stronger spiritual wellbeing and metaphysical beliefs in an observational study that did not establish causality.

In a phase 3 trial of 214 adults with generalized anxiety disorder, a single dose of DT120 orally disintegrating tablets produced greater reductions in anxiety scores than placebo through 12 weeks. Full peer-reviewed data and longer-term results remain pending.

A Phase 2 trial of luvesilocin reported rapid reductions in postpartum depression symptoms, with most treated participants reaching remission within seven days. The investigational psychedelic has received FDA Breakthrough Therapy designation, but Phase 3 confirmation remains pending.

A single dose of an investigational LSD formulation was associated with greater improvement in depressive symptoms than placebo in a phase 3 trial of adults with major depressive disorder. The findings are based on topline company-reported results and await full peer-reviewed publication.